A Japanese approach for CKD-MBD

Keitaro Yokoyama, Masatomo Taniguchi, Masafumi Fukagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Disturbances in mineral and bone metabolism have a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term 'renal osteodystrophy' has recently been replaced by 'CKD-mineral and bone disorder (CKD-MBD)', which includes abnormalities in bone and mineral metabolism and vascular calcification. The Japanese Society for Dialysis Therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in Japanese in 2006, then in English in 2008. During the past 5 years, this first guideline has contributed to a considerably better understanding and control of secondary hyperparathyroidism in CKD patients by physicians, other medical professionals, and the patients themselves. However, since its publication several new therapeutic modalities have become available for Japanese dialysis patients, which added more evidence to this area. Thus, we revised the guideline to include several new policies, and the new guideline was published in Japanese in 2012. This article contains the new guideline text, and clinical significance of CKD-MBD in Japan.

Original languageEnglish (US)
Pages (from-to)451-456
Number of pages6
JournalKidney International Supplements
Volume3
Issue number5
DOIs
StatePublished - Dec 2 2013

Fingerprint

Chronic Renal Insufficiency
Guidelines
Chronic Kidney Disease-Mineral and Bone Disorder
Dialysis
Secondary Hyperparathyroidism
Minerals
Vascular Calcification
Bone and Bones
Practice Management
Practice Guidelines
Publications
Japan
Physicians
Therapeutics

Keywords

  • Calcium
  • CKD-MBD
  • Guideline
  • Parathyroid hormone
  • Phosphorus
  • The Japanese Society for Dialysis Therapy

ASJC Scopus subject areas

  • Nephrology

Cite this

Yokoyama, K., Taniguchi, M., & Fukagawa, M. (2013). A Japanese approach for CKD-MBD. Kidney International Supplements, 3(5), 451-456. https://doi.org/10.1038/kisup.2013.94

A Japanese approach for CKD-MBD. / Yokoyama, Keitaro; Taniguchi, Masatomo; Fukagawa, Masafumi.

In: Kidney International Supplements, Vol. 3, No. 5, 02.12.2013, p. 451-456.

Research output: Contribution to journalArticle

Yokoyama, K, Taniguchi, M & Fukagawa, M 2013, 'A Japanese approach for CKD-MBD', Kidney International Supplements, vol. 3, no. 5, pp. 451-456. https://doi.org/10.1038/kisup.2013.94
Yokoyama, Keitaro ; Taniguchi, Masatomo ; Fukagawa, Masafumi. / A Japanese approach for CKD-MBD. In: Kidney International Supplements. 2013 ; Vol. 3, No. 5. pp. 451-456.
@article{d4d1c4a7964d4243be6c12cb5411ad61,
title = "A Japanese approach for CKD-MBD",
abstract = "Disturbances in mineral and bone metabolism have a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term 'renal osteodystrophy' has recently been replaced by 'CKD-mineral and bone disorder (CKD-MBD)', which includes abnormalities in bone and mineral metabolism and vascular calcification. The Japanese Society for Dialysis Therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in Japanese in 2006, then in English in 2008. During the past 5 years, this first guideline has contributed to a considerably better understanding and control of secondary hyperparathyroidism in CKD patients by physicians, other medical professionals, and the patients themselves. However, since its publication several new therapeutic modalities have become available for Japanese dialysis patients, which added more evidence to this area. Thus, we revised the guideline to include several new policies, and the new guideline was published in Japanese in 2012. This article contains the new guideline text, and clinical significance of CKD-MBD in Japan.",
keywords = "Calcium, CKD-MBD, Guideline, Parathyroid hormone, Phosphorus, The Japanese Society for Dialysis Therapy",
author = "Keitaro Yokoyama and Masatomo Taniguchi and Masafumi Fukagawa",
year = "2013",
month = "12",
day = "2",
doi = "10.1038/kisup.2013.94",
language = "English (US)",
volume = "3",
pages = "451--456",
journal = "Kidney International Supplements",
issn = "2157-1724",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A Japanese approach for CKD-MBD

AU - Yokoyama, Keitaro

AU - Taniguchi, Masatomo

AU - Fukagawa, Masafumi

PY - 2013/12/2

Y1 - 2013/12/2

N2 - Disturbances in mineral and bone metabolism have a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term 'renal osteodystrophy' has recently been replaced by 'CKD-mineral and bone disorder (CKD-MBD)', which includes abnormalities in bone and mineral metabolism and vascular calcification. The Japanese Society for Dialysis Therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in Japanese in 2006, then in English in 2008. During the past 5 years, this first guideline has contributed to a considerably better understanding and control of secondary hyperparathyroidism in CKD patients by physicians, other medical professionals, and the patients themselves. However, since its publication several new therapeutic modalities have become available for Japanese dialysis patients, which added more evidence to this area. Thus, we revised the guideline to include several new policies, and the new guideline was published in Japanese in 2012. This article contains the new guideline text, and clinical significance of CKD-MBD in Japan.

AB - Disturbances in mineral and bone metabolism have a critical role in the pathogenesis of cardiovascular complications in patients with chronic kidney disease (CKD). The term 'renal osteodystrophy' has recently been replaced by 'CKD-mineral and bone disorder (CKD-MBD)', which includes abnormalities in bone and mineral metabolism and vascular calcification. The Japanese Society for Dialysis Therapy clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients was originally published in Japanese in 2006, then in English in 2008. During the past 5 years, this first guideline has contributed to a considerably better understanding and control of secondary hyperparathyroidism in CKD patients by physicians, other medical professionals, and the patients themselves. However, since its publication several new therapeutic modalities have become available for Japanese dialysis patients, which added more evidence to this area. Thus, we revised the guideline to include several new policies, and the new guideline was published in Japanese in 2012. This article contains the new guideline text, and clinical significance of CKD-MBD in Japan.

KW - Calcium

KW - CKD-MBD

KW - Guideline

KW - Parathyroid hormone

KW - Phosphorus

KW - The Japanese Society for Dialysis Therapy

UR - http://www.scopus.com/inward/record.url?scp=84896711743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896711743&partnerID=8YFLogxK

U2 - 10.1038/kisup.2013.94

DO - 10.1038/kisup.2013.94

M3 - Article

C2 - 25019029

AN - SCOPUS:84896711743

VL - 3

SP - 451

EP - 456

JO - Kidney International Supplements

JF - Kidney International Supplements

SN - 2157-1724

IS - 5

ER -